tirzepatide and kidney linked to lower risk for death, adverse CV outcomes vs. GLP-1s Tirzepatide Significantly Reduces Mortality and

Comparing these two trials, after 40 weeks, participants on semaglutide lost an average of 6.9 kg, whereas those on tirzepatide lost 7.8, 10.3, or 12.4 kg, respectively

However, levels were significantly increased in PBH in both the fasting state and after 120 minutes, potentially reflecting increased fatty acid oxidation with fasting, an accelerated return to fasting physiology after meals (despite high postprandial insulin levels), and protective adaptation to provide alternative fuels in the setting of recurrent hypoglycemia (23)

Currently, there is no official contraindication to using GLP-1 medications in patients with Hashimoto's thyroiditis

It's important to consider the timing and method of taking these medications

Tirzepatide works by activating GLP-1 and GIP receptors, hormones that regulate both appetite and blood sugar